JARDIANCE® provides triple protection in your patients with CRM conditions:
reduced risk of CV death
or kidney disease progression*1,2
reduced risk of CV death
or hospitalisation for heart failure†3,4
reduced risk of CV death‡5
Prof. Christoph Wanner - What is a typical patient that may benefit from the EMPA-KIDNEY trial results?
14/03/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-103564